SKITUDE
4.6.2019 16:46:10 CEST | Business Wire | Press release
The merger of Skitude, the largest network of skiing apps, and the Skioo innovative skipass technology, which provides access to ski resorts with a single card and no waiting in line, aims to optimise sales channels for the more than 150 partnering ski resorts for the upcoming season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190604005775/en/
Alongside may other advantages, the strategy will consist of using post-payment systems to facilitate the user’s skiing experience, streamlining their access to the slopes, and helping the ski resorts position their products on their online platform.
“We are working so that skiers can purchase a ski pass ahead of time and load the ticket on their RFID card, or validate beforehand using a credit card, easily from their mobile on”, explained Skitude CEO Marc Bigas. “These principles of convenience and post-payment are already well-known thanks to popular services like Uber”, he added.
As a result, Skitude Chairman Yngve Tvedt explains, the combined digital platform will add a new dimension to the ski industry with a digital journey that is simpler and fun.
Thus, Tvedt assures, Skitude is participating in the “digitalisation of the sector” and agrees with Marc Bigas that this experience will offer “more convenience to the skier” as well as “powerful solutions for the mobile sales channels and marketing services” that will help ski resorts stay better connected with the needs of their current and potential customers.
New challenges
The merger of the two companies is also aimed at finding a way to push back against the stagnation of users in the industry, one of the sector's main challenges. “We are setting off on a journey to meet challenges using technology”, the company’s CEO stated, adding that the experience built up by both Skitude and Skioo over the years will become “valuable information for ski resorts”.
It is worth noting that the Girona-based company has always been committed to interacting with users “before, during and after their visit”, which, according to Bigas, “strengthens the competitiveness of the industry and enables it to continue moving forward”.
A community of more than 1.3 million skiers
The Skitude community is currently made up of more than 1.3 million skiers who have used the free applications that are compatible with the Skitude platform, most of them being the official applications of ski resorts.
It is a very active community. Thanks to the GPS Tracker that can log their runs, users have already logged activity at more than 1,200 ski resorts in 45 countries worldwide, and have been able to participate in more than 250 Challenges allowing them to win ski days, equipment like skis, boots or action cameras, and exclusive discounts.
The operation will allow consolidating the international project of 50 people, with offices in Girona, Lausanne and Oslo, and to continue researching to find dynamic solutions and improve the customer experience at ski resorts.
The shareholders of the company are comprised of the entrepreneurial partners Marc Bigas and David Huerva, Spanish investment funds, as well as the three Norwegian funds that own Skioo: Investinor, Canica and Norselab. Norselab counts the Olympic alpine ski champion Aksel Lund Svindal as an investor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005775/en/
Contact:
For more information: Àric Monterde +34-972-001-021 aric.monterde@skitude.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom